Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9756740 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP2C19TNFRSF1AMAPTSMN1; SMN2 | |
| SCHEMBL6989989 | 0.81 | TNFRSF1A (0.72) | CYP1A2CYP2C19TNFRSF1AMAPTSMN1; SMN2 | |
| SCHEMBL6989990 | 0.81 | TNFRSF1A (0.72) | CYP1A2CYP2C19TNFRSF1AMAPTSMN1; SMN2 | |
| SCHEMBL11429551 | 0.81 | MAPT (0.58) | CYP1A2CYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11490304 | 0.81 | MAPT (0.58) | CYP1A2CYP2C19MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5197267 | 0.80 | RECQL (0.55) | TNFRSF1AMAPTSMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL5197269 | 0.80 | RECQL (0.55) | TNFRSF1AMAPTSMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL9519390 | 0.79 | F3 (0.64) | TNFRSF1AMAPTALDH1A1MAOAMAOB | |
| SCHEMBL11298787 | 0.79 | F3 (0.64) | TNFRSF1AMAPTALDH1A1MAOAMAOB | |
| SCHEMBL956091 | 0.78 | CYP1A2 (0.63) | CYP1A2CYP2C19TNFRSF1AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072392-A1 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-9540350-B2 | 1-substituted, 4-(substituted phenoxymethyl)-1,2,3-triazole compounds with antifungal properties and methods for preparation thereof | FDC LIMITED (IN) | 2017-01-10 | — | — | US | disclosed |
| US-20160009692-A1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | FDC LIMITED (IN) | 2016-01-14 | — | — | US | disclosed |
| US-4992462-A | Inhibitor of HMG-CoA reductase | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-12 | — | — | US | disclosed |
| EP-0287890-A1 | Substituted pyrroles | BAYER AG (DE) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009692-A1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | ERG28, CYP51A1, CYP2E1 | CYP1A2 30/4885CYP2C19 78/4885TNFRSF1A 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.